AAV1-LPLS447X gene therapy reduces hypertriglyceridemia in apoE2 knock in mice

Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids

Volumn 1761, Issue 10, 2006, Pages 1163-1168

  Rip, Jaap ^a   van Dijk, Ko Willems ^b   Sierts, Jeroen A ^a   Kastelein, John J P ^a   Twisk, Jaap ^c   Kuivenhoven, Jan Albert ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c Amsterdam Molecular Therapeutics   (Netherlands)

Author keywords

Adeno associated virus; Dyslipidemia; Gene transfer; Lipoprotein lipase

Indexed keywords

APOLIPOPROTEIN E2; HUMAN LIPOPROTEIN LIPASE; LIPOPROTEIN LIPASE; PARVOVIRUS VECTOR; UNCLASSIFIED DRUG;

ADENO ASSOCIATED VIRUS; ADENO ASSOCIATED VIRUS SEROTYPE 1; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DYSLIPIDEMIA; FEMALE; HUMAN; HUMAN CELL; HYPERTRIGLYCERIDEMIA; KNOCKOUT MOUSE; LIPID BLOOD LEVEL; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

ANIMALS; APOLIPOPROTEIN E2; DEPENDOVIRUS; FEMALE; GENE THERAPY; GENETIC VECTORS; HUMANS; HYPERTRIGLYCERIDEMIA; INJECTIONS, INTRAMUSCULAR; LIPIDS; LIPOPROTEIN LIPASE; MICE; MICE, TRANSGENIC; MUSCLES; TRIGLYCERIDES;

ADENO-ASSOCIATED VIRUS;

EID: 33749451873     PISSN: 13881981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbalip.2006.08.008     Document Type: Article

References (24)

1. Goldberg I.J. Lipoprotein lipase and lipolysis: central roles in lipoprotein metabolism and atherogenesis. J. Lipid Res. 37 (1996) 693-707
2. Beisiegel U., Weber W., and Bengtsson-Olivecrona G. Lipoprotein lipase enhances the binding of chylomicrons to low density lipoprotein receptor-related protein. Proc. Natl. Acad. Sci. U. S. A. 88 (1991) 8342-8346
3. Zheng C., Murdoch S.J., Brunzell J.D., and Sacks F.M. Lipoprotein lipase bound to apolipoprotein B lipoproteins accelerates clearance of postprandial lipoproteins in humans. Arterioscler. Thromb. Vasc. Biol. 26 (2006) 891-896
4. Weinstock P.H., Bisgaier C.L., Aalto-Setala K., Radner H., Ramakrishnan R., Levak-Frank S., Essenburg A.D., Zechner R., and Breslow J.L. Severe hypertriglyceridemia, reduced high density lipoprotein, and neonatal death in lipoprotein lipase knockout mice. Mild hypertriglyceridemia with impaired very low density lipoprotein clearance in heterozygotes. J. Clin. Invest. 96 (1995) 2555-2568
5. Coleman T., Seip R.L., Gimble J.M., Lee D., Maeda N., and Semenkovich C.F. COOH-terminal disruption of lipoprotein lipase in mice is lethal in homozygotes, but heterozygotes have elevated triglycerides and impaired enzyme activity. J. Biol. Chem. 270 (1995) 12518-12525
6. S447X beneficial mutation. Arterioscler. Thromb. Vasc. Biol. 25 (2005) 2143-2150
7. Christophersen B., Nordstoga K., Shen Y., Olivecrona T., and Olivecrona G. Lipoprotein lipase deficiency with pancreatitis in mink: biochemical characterization and pathology. J. Lipid Res. 38 (1997) 837-846
8. Ginzinger D.G., Lewis M.E., Ma Y., Jones B.R., Liu G., and Jones S.D. A mutation in the lipoprotein lipase gene is the molecular basis of chylomicronemia in a colony of domestic cats. J. Clin. Invest. 97 (1996) 1257-1266
9. Brunzell J. Familial Lipoprotein Lipase Deficiency and Other Causes of the Chylomicronemia Syndrome. In: Sriver C., Baudet A., Sly W., and Valle D. (Eds). The Metabolic and Molecular Basis of Inherited Disease. 7th ed. (1995), McGraw-Hill, New York 1913-1932
10. Mahley R.W., and Rall S.C. Type III Hyperlipoproteinaemia (Dyslipoproteinemia; Remnant Particle Disease). In: Betteridge D.J., Illingworth D.R., and Shepherd J.A. (Eds). Lipoproteins in Health and Disease (1999), Arnold Publishers, London, Great Britain 719-736
11. Weisgraber K.H., Innerarity T.L., and Mahley R.W. Abnormal lipoprotein receptor-binding activity of the human E apoprotein due to cysteine-arginine interchange at a single site. J. Biol. Chem. 257 (1982) 2518-2521
12. Morganroth J., Levy R.I., and Fredrickson D.S. The biochemical, clinical, and genetic features of type III hyperlipoproteinemia. Ann. Intern. Med. 82 (1975) 158-174
13. Zhang H., Reymer P.W., Liu M.S., Forsythe I.J., Groenemeyer B.E., Frohlich J., Brunzell J.D., Kastelein J.J., Hayden M.R., and Ma Y. Patients with apoE3 deficiency (E2/2, E3/2, and E4/2) who manifest with hyperlipidemia have increased frequency of an Asn 291→Ser mutation in the human LPL gene. Arterioscler. Thromb. Vasc. Biol. 15 (1995) 1695-1703
14. Brummer D., Evans D., Berg D., Greten H., Beisiegel U., and Mann W.A. Expression of type III hyperlipoproteinemia in patients homozygous for apolipoprotein E-2 is modulated by lipoprotein lipase and postprandial hyperinsulinemia. J. Mol. Med. 76 (1998) 355-364
15. Mann W.A., Meyer N., Berg D., Greten H., and Beisiegel U. Lipoprotein lipase compensates for the defective function of apo E variants in vitro by interacting with proteoglycans and lipoprotein receptors. Atherosclerosis 145 (1999) 61-69
16. Sullivan P.M., Mezdour H., Quarfordt S.H., and Maeda N. Type III hyperlipoproteinemia and spontaneous atherosclerosis in mice resulting from gene replacement of mouse Apoe with human Apoe*2. J. Clin. Invest. 102 (1998) 130-135
17. Ross C.J., Twisk J., Meulenberg J.M., Liu G., van den O.K., Moraal E., Hermens W.T., Rip J., Kastelein J.J., Kuivenhoven J.A., and Hayden M.R. Long-term correction of murine lipoprotein lipase deficiency with AAV1-mediated gene transfer of the naturally occurring LPL(S447X) beneficial mutation. Hum. Gene Ther. 15 (2004) 906-919
18. Ross C.J., Twisk J., Bakker A.C., Miao F., Verbart D., Rip J., Godbey T., Dijkhuizen P., Hermens W.T., Kastelein J.J., Kuivenhoven J.A., Meulenberg J.M., and Hayden M.R. Correction of feline lipoprotein lipase deficiency with adeno-associated virus serotype 1-mediated gene transfer of the lipoprotein lipase S447X beneficial mutation. Hum. Gene Ther. 17 (2006) 487-499
19. Rip J., Nierman M.C., Sierts J.A., Petersen W., Den Oever K.V., Raalte D.V., Ross C.J., Hayden M.R., Bakker A.C., Dijkhuizen P., Hermens W.T., Twisk J., Stroes E., Kastelein J.J., Kuivenhoven J.A., and Meulenberg J.M. Gene therapy for lipoprotein lipase deficiency: working toward clinical application. Hum. Gene Ther. 16 (2005) 1276-1286
20. Levels J.H., Abraham P.R., van den E.A., and van Deventer S.J. Distribution and kinetics of lipoprotein-bound endotoxin. Infect. Immun. 69 (2001) 2821-2828
21. Liu G., Ashbourne Excoffon K.J., Wilson J.E., McManus B.M., Rogers Q.R., Miao L., Kastelein J.J., Lewis M.E., and Hayden M.R. Phenotypic correction of feline lipoprotein lipase deficiency by adenoviral gene transfer. Hum. Gene Ther. 11 (2000) 21-32
22. Bligh E., and Dyer W. A rapid method of total lipid extraction and purification. Can. J. Med. Sci. 37 (1959) 911-917
23. Levak-Frank S., Radner H., Walsh A., Stollberger R., Knipping G., Hoefler G., Sattler W., Weinstock P.H., Breslow J.L., and Zechner R. Muscle-specific overexpression of lipoprotein lipase causes a severe myopathy characterized by proliferation of mitochondria and peroxisomes in transgenic mice. J. Clin. Invest. 96 (1995) 976-986
24. Hoefler G., Noehammer C., Levak-Frank S., el Shabrawi Y., Schauer S., Zechner R., and Radner H. Muscle-specific overexpression of human lipoprotein lipase in mice causes increased intracellular free fatty acids and induction of peroxisomal enzymes. Biochimie 79 (1997) 163-168